Dr Reddys Laboratories (RDY) Profit After Tax (2009 - 2023)

Dr Reddys Laboratories (RDY) has reported Profit After Tax for 15 consecutive years, with $170.0 million the latest figure, recorded in Q2 2023.

• Quarterly Profit After Tax changed N/A year-over-year to $170.0 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $459.0 million (changed N/A YoY) and the FY2026 annual result came in at $452.0 million, down 32.64% from the prior year.
• Profit After Tax eased to $170.0 million in Q2 2023 per RDY's latest filing, from $172.0 million in the prior quarter.
• Over the last five years, Profit After Tax for RDY reached as high as $172.0 million in Q1 2023 and fell as low as -$78.0 million in Q3 2020.
• A 5-year average of $92.8 million and a median of $110.5 million in 2019 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2019 — Profit After Tax jumped 131.82% — and 2020, when it slumped 214.71%.
• Year by year, Profit After Tax stood at $68.0 million in 2019, then sank by 214.71% to -$78.0 million in 2020, then soared by 271.79% to $134.0 million in 2021, then fell by 12.69% to $117.0 million in 2022, then surged by 45.3% to $170.0 million in 2023.
• According to Business Quant data, Profit After Tax over the past three periods registered $170.0 million, $172.0 million, and $117.0 million for Q2 2023, Q1 2023, and Q4 2022 respectively.